Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes and cancer – not again?

February 18th 2012

In 2010, the medical press was full of stories concerning a link between the long-acting insulin analogue, glargine, and various forms of cancer. A year later, the French authorities banned pioglitazone, on the basis that it might increase the risk of bladder cancer. Although neither of these links have been substantiated (and both agents remain part of NICE guidance in the UK), the spectre of increased cancer risk has now fallen on a novel diabetes pipeline agent, threatening to slow its launch.

Dapagliflozin is the first in class of specific sodium-glucose transporter (SGLT-2) inhibitors, a group of drugs which improve glycaemia by inhibiting glucose reabsorption in the kidney. As a result, there is increased glucose loss in the urine (glycosuria) and, via urinary enhanced calorie loss, weight reduction in the order of 2-3Kg. These effects, from a once daily oral medication, with the potential for use with insulin (and hence in type 1 diabetes) are an attractive therapeutic option.

Unfortunately, pooled data from early phase clinical trials show an ‘imbalance’ in risk for bladder and breast cancer. Although these differences are non-significant, have no plausible biological basis, were not seen in animal studies and did not result in an overall increase in trial cancer outcomes (which were identical), the FDA requires more data and licensing will be delayed, in the US at least.
Whilst safety vigilance is essential, there is a real possibility that all of the large on-going cardiovascular trials for new diabetes medications could show a statistical ‘imbalance’ in one of the many parameters being assessed. How to manage this is a major challenge for the licensing authorities…

Professor Steve Bain

 

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNovo NordiskNapp DiabetesSanofi Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenAbout Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership